College of Pharmacy, Anhui University of Chinese Medicine and Anhui Academy of Chinese Medicine, Hefei 230012, China; Engineering Technology Research Center of Modernized Pharmaceutics, Anhui Province, China.
College of Pharmacy, Anhui University of Chinese Medicine and Anhui Academy of Chinese Medicine, Hefei 230012, China; Engineering Technology Research Center of Modernized Pharmaceutics, Anhui Province, China.
J Control Release. 2020 Apr 10;320:1-18. doi: 10.1016/j.jconrel.2020.01.007. Epub 2020 Jan 10.
The protein corona significantly changes the nanoparticle (NP) identity both physicochemically and biologically, and in situ regulation of specific plasma protein adsorption on NP surfaces has emerged as a promising strategy for disease-targeting therapy. In the past decade, great progress in protein corona regulation has been achieved via surface chemistry-based nanomedicine development. This review first outlines the latest advances in bio-nano interactions, with special attention to factors that influence the protein corona, including NP physicochemical properties, the biological environment and the duration time. Second, NP surface chemistry strategies designed to inhibit and regulate protein corona formation are highlighted, with special emphasis on albumin, transferrin, apolipoprotein (apo) E, vascular endothelial growth factor (VEGF) and retinol binding protein 4 (RBP4). Finally, the current techniques used to characterize the protein corona are briefly discussed.
蛋白质冠显著改变了纳米颗粒(NP)的物理化学和生物学特性,而在 NP 表面原位调节特定血浆蛋白的吸附已成为一种有前途的疾病靶向治疗策略。在过去的十年中,通过基于表面化学的纳米医学发展,在蛋白质冠调控方面取得了巨大进展。本综述首先概述了生物-纳米相互作用的最新进展,特别关注影响蛋白质冠的因素,包括 NP 的物理化学性质、生物环境和时间。其次,重点介绍了设计用于抑制和调节蛋白质冠形成的 NP 表面化学策略,特别强调了白蛋白、转铁蛋白、载脂蛋白(apo)E、血管内皮生长因子(VEGF)和视黄醇结合蛋白 4(RBP4)。最后,简要讨论了目前用于表征蛋白质冠的技术。